Ligase Engineering and Production
As a leading service provider in drug discovery and development, BOC Sciences is fully qualified and committed to providing one-stop PROTAC® development services, which has become a promising strategy in the field of small molecular drug discovery. With a comprehensive and advanced platform, we provide E3 Ligase engineering and production to customers around the world to meet new drug discovery goals.
Introduction
Enzyme engineering, also known as protein engineering, refers to an applied technology that purposefully sets up certain reactors and reaction conditions in industry, makes use of the catalytic function of enzymes to catalyze chemical reactions under certain conditions, and produces products needed by human beings or serves other purposes. Ligase engineering refers to the products related to ligases and the processes and services by which ligases are linked to target proteins or other molecules. The Ubiquitin ligase, also known as E3 ubiquitin ligase, is an enzyme that connects ubiquitin molecules to a lysine of the target protein.
Application
The mono-ubiquitin modification and polyubiquitin modification of the substrate can be made according to the relative ratio of E3 to the substrate. The target protein modified by polyubiquitin is generally degraded by 26S proteasome. This pathway is called ubiquitin proteasome pathway, or ubiquitin pathway for short. Polyubiquitin-modified target proteins (such as denatured, misfolded or overexpressed proteins and many regulatory proteins in cells) can be degraded through ubiquitin pathway and play an important role in cell cycle regulation, endocytosis, signal transduction, DNA repair, protein quality control (such as Bsd2 plays an important role in the quality control of membrane proteins) and apoptosis.
Our Advantages
- Advanced equipment and technique
- Multiple enzyme modification technology
- High quality multiple E3 ligase
- Experienced scientific team
- Quality one-stop service
- High Quality and Cost-Effective Choices
- The advanced ligand design and synthesis platform
- Highly reliable and reproducible results
- Data analysis, detailed report with results and discussion
References:
- Gorelik, M., & Sidhu, S. S. (2017). Specific targeting of the deubiquitinase and E3 ligase families with engineered ubiquitin variants. Bioengineering & translational medicine, 2(1), 31-42.
- Berndsen, C. E., & Wolberger, C. (2014). New insights into ubiquitin E3 ligase mechanism. Nature structural & molecular biology, 21(4), 301.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
